Jove
Visualize
Contact Us

Related Concept Videos

Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

677
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
677
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

451
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
451
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

828
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
828
Bipolar Disorder01:30

Bipolar Disorder

628
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
628
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

730
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
730
Depression: Overview01:18

Depression: Overview

794
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
794

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.

Human brain mapping·2026
Same author

Decomposing neuroanatomical heterogeneity in depression: insights from an ENIGMA major depressive disorder working group study in 5146 individuals.

Translational psychiatry·2026
Same author

A canary in the mind: A single baseline brain scan predicts adolescent depression and anxiety one year later.

medRxiv : the preprint server for health sciences·2026
Same author

On the value of radiomics in addition to clinical measures in emotional conflict fMRI for predicting sertraline response in major depressive disorder.

Scientific reports·2026
Same author

Network and receptor architectures shape brain morphometry in addiction.

medRxiv : the preprint server for health sciences·2026
Same author

Schooling Trajectories and the Development of Brain Dynamics: A Comparative Study of Montessori and Traditional Education.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 17, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.5K

Turbulent-like Dynamics Predict Treatment Outcome in Major Depressive Disorder.

Henricus Ruhe1, Maarten Poirot, Yonatan Sanz Perl2

  • 1Radboudumc.

Research Square
|September 18, 2025
PubMed
Summary

Brain turbulence measures can predict antidepressant response in major depressive disorder patients. However, this prediction method showed limited specificity to sertraline treatment, suggesting further research is needed.

Keywords:
Antidepressant Treatment ResponseMachine LearningMajor Depressive DisorderResting State Functional Magnetic Resonance ImagingTurbulence

More Related Videos

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.1K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.3K

Related Experiment Videos

Last Updated: Jan 17, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.5K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.1K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.3K

Area of Science:

  • Neuroscience
  • Computational Psychiatry
  • Medical Imaging

Background:

  • Major depressive disorder (MDD) is a widespread and disabling condition.
  • Treatment selection for MDD often involves a lengthy trial-and-error process.
  • Identifying predictors of treatment response is crucial for reducing the burden of MDD.

Purpose of the Study:

  • To investigate brain turbulence-like dynamic measures as potential predictors of antidepressant treatment response in MDD.
  • To assess the efficacy of these measures in predicting response to sertraline treatment.

Main Methods:

  • Analysis of resting-state functional MRI data from 296 adult outpatients in the EMBARC study, treated with sertraline or placebo.
  • Computation of turbulence-like dynamic measures from fMRI scans acquired at baseline and one week post-treatment.
  • Use of generalized linear models to predict treatment response and symptom severity at week 8, with internal and external cross-validation.

Main Results:

  • Internal cross-validation in sertraline-treated patients showed significant prediction of response (AUROC=0.71) and symptom severity (RMSE=4.7).
  • External validation in the placebo group did not yield significant prediction performance.
  • External validation in a subgroup of placebo non-responders who switched to sertraline showed significant prediction of response (AUROC=0.65).

Conclusions:

  • The turbulence framework shows promise as a method for predicting sertraline response in MDD.
  • The predictive performance of turbulence measures demonstrated limited specificity to sertraline treatment.
  • MDD patients who did not respond to sertraline exhibited distinct patterns of information cascade flow (increased long-distance, reduced short-distance).